



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Toshiki Murata, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP2003/011976

Title: Phenyl or Heteroaryl Amino Alkane Derivatives as IP Receptor Antagonist

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF DATE OF NATIONAL STAGE ENTRY (37 C.F.R. 1.97(b))

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying modified form PTO-1449. A copy of the International Search Report is also enclosed for your reference.

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed concurrently with the request under 35 U.S.C. § 371(f) to begin national examination procedures.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

William F. Gray Reg. No.: 31,018

Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation 400 Morgan Lane West Haven, CT 06516 Telephone: (203) 812-2712 Facsimile: (203) 812-6459

JC14 Rec'd PCT/PTO 0 6 MAY 2005

Form PTC (Modified)-1449 l)		U.	I.S Pa	rtmen d Tra	t of Co demark	ommerce Office	e ;	Serial No.	Art U		Filing D 05/06/2		RCK-38	'До.] 8
INFORMATION DISCLOSURE CITATION									Applicant(s) Toshiki MURATA, et al.						
								S. P/	ATENT DOCU	•					
	 	<u> </u>		DOC	UMEN	T NO.			DATE	NAME			SUB-	FILING I	
*		- I							(MM/DD/YY)				CLASS	IF APPROPE	
U1	2002	0	0	5	8	6	0	6	05/16/02	Gonzalez et a	al.	514	1	01/12	_
180 8	U2	4	2	5	9	4	8	9	03/31/81	Takematsu et	al.	544	336	12/15	/78
	1									-					
			<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>							
		ļ		<u> </u>	<u> </u>	<u> </u>		-					_		
Admidit .				<u> </u>	<u></u> '	<u> </u>	<u> </u>	<u> </u>		·		<u> </u>	<u> </u>		
							ORE	IGN	N PATENT DO		T 700	TARV	SUB-	TRANSL	ATION
*			DOCUMENT NO.						DATE (DD/MM/YY)	COUNTRY		IMARY CLASS	CLASS	YES	NO
	F1	2	3	2	3	8	4	2	07/10/98	GB					
	F2	0	2	4	0	0	0	8	23/05/02	wo					
	F3	9	6	3	3	9	7	2		WO					
	F4	0	2	0	9	6	9	33		WO					
	F5	0	0	4	3	3	7	2		WO					
	F6	0	1	6	8	5	9	1	20/09/01	wo	_			-	
			<u> </u>								<u> </u>				
			OTH	ER P	(EFE	RENC	CES (Incl	uding Author,	Γitle, Date, Per	rtine	nt Pages.	, etc.)	***	
	R1	DA'	ГАВ <i>А</i> ОО22	ASE C 26815:	CAPLI 3, RN	US [O s 209!	Inline 982-8], CI 9-8,	HEMICAL ABS 209982-90-1, &	TRACTS SERVING 98 28268	VICE A 2 J	E, COLU uly 1998	MBUS, O (1998-07	HIO, US; -02)	
	R2	Tera	anishi	i. K "	"Effec	ct of co	onforr	matic	on on the chemil	luminescence ef	fficie	ency of lig	ght-produc	cing 2-met	thyl-6
		(4-r	netho	xy-ph	enyl)i	mida	zo[1,2	<u>2-α]p</u>	yrazin-3(7H)-or	nes", Luminesce	ence,	<u>16</u> : 367	-374 (200	1)	
	+	 													
	-	 													
	-	<u> </u>													
		<u> </u>													
EXAMIN	JER								DATE	CONSIDERED					

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.